Mulya.ai
Ticker
WST
Scenario
Key Inputs
Revenue est.?Analysttaper yr5
OP margin est.?Analyst
Reinvestment est.?projected
R&D capitalizedNo
Leases factoredNo
Key Assumptions
WACC ?9.4%
ERP ?4.5%
Risk-free rate ?4.1%
Beta (blended) ?1.182
Beta (levered) ?1.190
Terminal OM% ?18.2%
Segment conc. ?81% dominant
Terminal growth ?4.1%
Bond rating ?AAA · 0.60%
ROIC option ?Opt 4 · 19.4%
Prob of failure ?0.0%
Pipeline validated · 2026-07-21

WST · West Pharmaceutical Services, Inc.

$350.852026-07-21
Sector: Healthcare; Industry: Medical - Instruments & Supplies; Sub-Industry: Health Care Supplies

Intrinsic Value Range Comparison · Mulya.ai

Bull
$158
-54.9% vs market
Base · active
$133
-62.0% vs market
Bear
$128
-63.6% vs market
Mulya.ai vs Analyst IV Comparison?
Bear $128
Base $133
Bull $158
Median $318
Market $351
Market Price $351
Mulya.ai Base $133
Analysts Median $318
Mulya.ai IV range ($128 · $158)
Analysts Range ($295 · $400)
Fundamentals · historical + forward · base
italics = DCF projection
PeriodRevenueRev Gr ?Ops M% ?Tax Rate ?NOPAT ?
Reinvest ?
FCFF ?WACC% ?PV FCFF ?ROIC ?Inv. Cap ?EPS ?P/E
2024.Q1$3.0B24.1%16.8%$591MM−$237MM$354MM9.2%25.7%$2.3B$8.20
2024.Q4$3.0B0.0%24.1%17.9%$584MM−$219MM$365MM9.5%24.7%$2.4B$8.20
2025.Q1$2.9B-2.0%20.6%19.8%$477MM−$161MM$316MM9.8%19.4%$2.5B$6.81
2025.Q4$2.9B0.0%20.6%19.8%$477MM−$50MM$427MM9.5%18.7%$2.6B$6.81
2026.Q1$3.2B11.3%20.7%20.9%$527MM−$119MM$408MM9.5%19.9%$2.7B$7.5038.2
italics below = DCF projection · 10yr Rev CAGR: 5.3%
2027.Q1$3.4B+5.1%20.1%20.8%$540MM−$79MM$462MM9.3%$422MM19.8%$2.8B$7.4647.0
2028.Q1$3.6B+6.3%20.1%20.7%$575MM−$118MM$457MM9.3%$382MM20.3%$2.9B$7.9444.2
2029.Q1$3.8B+7.0%20.1%20.6%$616MM−$168MM$448MM9.2%$343MM20.7%$3.1B$8.5041.3
2030.Q1$4.1B+5.7%20.1%20.5%$652MM−$136MM$515MM9.1%$362MM20.9%$3.2B$9.0039.0
2031.Q1$4.3B+5.5%20.1%20.4%$688MM−$146MM$542MM9.0%$350MM21.1%$3.3B$9.5036.9
Term. Yr+$5.6B4.1%18.2%20.0%$817MM−$173MM$644MM8.6%$6.1B19.4%
Active scenario IV: $133 (-62.0% vs market)